 |
PDBsum entry 4c1f
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of the metallo-beta-lactamase imp-1 with l-captopril
|
|
Structure:
|
 |
Beta-lactamase imp-1. Chain: a, b. Fragment: residues 19-245. Synonym: imp-1, blaimp, beta-lactamase type ii, penicillinase. Engineered: yes
|
|
Source:
|
 |
Serratia marcescens. Organism_taxid: 615. Expressed in: escherichia coli. Expression_system_taxid: 469008. Expression_system_variant: plyss. Other_details: plasmid derived non-genomic.
|
|
Resolution:
|
 |
|
2.01Å
|
R-factor:
|
0.186
|
R-free:
|
0.224
|
|
|
Authors:
|
 |
D.Zollman,J.Brem,M.A.Mcdonough,S.S.Van Berkel,C.J.Schofield
|
|
Key ref:
|
 |
J.Brem
et al.
(2015).
Structural Basis of Metallo-β-Lactamase Inhibition by Captopril Stereoisomers.
Antimicrob Agents Chemother,
60,
142-150.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
12-Aug-13
|
Release date:
|
27-Aug-14
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P52699
(BLAB_SERMA) -
Metallo-beta-lactamase type 2 from Serratia marcescens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
246 a.a.
219 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Antimicrob Agents Chemother
60:142-150
(2015)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural Basis of Metallo-β-Lactamase Inhibition by Captopril Stereoisomers.
|
|
J.Brem,
S.S.van Berkel,
D.Zollman,
S.Y.Lee,
O.Gileadi,
P.J.McHugh,
T.R.Walsh,
M.A.McDonough,
C.J.Schofield.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
β-Lactams are the most successful antibacterials, but their effectiveness is
threatened by resistance, most importantly by production of serine- and
metallo-β-lactamases (MBLs). MBLs are of increasing concern because they
catalyze the hydrolysis of almost all β-lactam antibiotics, including
recent-generation carbapenems. Clinically useful serine-β-lactamase inhibitors
have been developed, but such inhibitors are not available for MBLs.
l-Captopril, which is used to treat hypertension via angiotensin-converting
enzyme inhibition, has been reported to inhibit MBLs by chelating the active
site zinc ions via its thiol(ate). We report systematic studies on B1 MBL
inhibition by all four captopril stereoisomers. High-resolution crystal
structures of three MBLs (IMP-1, BcII, and VIM-2) in complex with either the l-
or d-captopril stereoisomer reveal correlations between the binding mode and
inhibition potency. The results will be useful in the design of MBL inhibitors
with the breadth of selectivity required for clinical application against
carbapenem-resistant Enterobacteriaceae and other organisms causing MBL-mediated
resistant infections.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |